The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the

Braxton D Mitchell1, Patrick F McArdle, Haiqing Shen

  • 1Division of Endocrinology, Department of Medicine, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. bmitchel@medicine.umaryland.edu

American Heart Journal
|April 29, 2008
PubMed

Insights

Cardiovascular disease (CVD) risk is influenced by genetics. The HAPI Heart Study found that some variation in how individuals respond to interventions like high salt or fat diets is heritable, suggesting genetic links to CVD risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Human Physiology

Background:

  • Cardiovascular disease (CVD) etiology is complex and multifactorial.
  • Previous genetic studies for CVD risk have had limited success due to small allele effects and gene interactions.
  • Gene by gene and gene by environment interactions complicate the identification of CVD risk factors.

Purpose of the Study:

  • To investigate cardiovascular responses to short-term interventions.
  • To identify genetic and environmental determinants of these cardiovascular responses.
  • To explore novel mechanisms influencing CVD risk.

Main Methods:

  • The HAPI Heart Study measured responses in 868 Amish adults.
  • Interventions included cold pressor test, high salt diet, high-fat challenge, and aspirin therapy.
  • Measurements assessed blood pressure, triglyceride levels, and platelet aggregation.

Main Results:

  • Heritability estimates for response traits ranged from 8% to 38%.
  • This indicates that additive gene effects contribute to individual variations in response to interventions.
  • Significant genetic influence on cardiovascular responses to various challenges was observed.

Conclusions:

  • Genetic factors play a role in cardiovascular responses to specific challenges.
  • Identifying genes associated with these responses may reveal new CVD mechanisms.
  • This research could pave the way for personalized prevention and early detection of high-risk individuals.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...